CHUGAI PHARMACEUTICAL CO., LTD. : Co-Development and Co-Marketing ... 4-traders GA101 is a glycoengineeredtype II anti-CD20 monoclonal antibody created by GlycArt AG and is a compound that selectively targets the CD20 protein on B-cells, same as rituximab (recombinant) which is recommended as a treatment of non-Hodgkin's ... |
